- ►annals.org [PDF] H Olschewski, HA Ghofrani, T Schmehl, J … - Annals of internal medicine, 2000 - Am Coll Physicians Horst Olschewski, MD; H. Ardeschir Ghofrani, MD; Thomas Schmehl, PhD; Jörg
Winkler, MD; Heinrike Wilkens, MD; Marius M. Höper, MD; Jürgen Behr, MD;
Franz-Xaver Kleber, MD; and Werner Seeger, MD, for the German PPH Study Group* Cited by 249 - Related articles - BL Direct - All 5 versions
- ►utmem.edu [PDF] MM Hoeper, M Schwarze, S Ehlerding, A … - New England Journal of Medicine, 2000 - content.nejm.org Results Twenty-four patients with primary pulmonary hypertension received
aerosolized iloprost at a daily dose of 100 or 150 µg for at least one year.
The mean (±SD) distance covered in the six-minute walk test increased from ... Cited by 457 - Related articles - BL Direct - All 11 versions
- ►annals.org H Olschewski, D Walmrath, R Schermuly, HA … - Annals of internal medicine, 1996 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To compare the effects of aerosolization of prostacyclin and its ... Cited by 339 - Related articles - All 5 versions
AU Trial - Ann Intern Med, 2000 - Am Coll Physicians Horst Olschewski, MD; H. Ardeschir Ghofrani, MD; Thomas Schmehl, PhD; Jörg
Winkler, MD; Heinrike Wilkens, MD; Marius M. Höper, MD; Jürgen Behr, MD;
Franz-Xaver Kleber, MD; and Werner Seeger, MD, for the German PPH Study Group* Related articles
- ►onlinejacc.org MM Hoeper, H Olschewski, HA Ghofrani, H … - Journal of the American College of Cardiology, 2000 - Elsevier Inhalation of the stable prostacyclin analogue iloprost has recently been
described as a novel therapeutic strategy for PPH and may offer an alternative
to continuous intravenous infusion of prostacyclin or inhalation of NO. Cited by 215 - Related articles - BL Direct - All 6 versions
H Olschewski, A GHOFRANI… - American journal of respiratory and critical care …, 1999 - ajrccm.org.p.angrylapdog.com Pulmonary hypertension is a life-threatening complication of lung fibrosis.
Vasodilator therapy is difficult owing to systemic side effects and pulmonary
ventilation-perfusion mismatch. We compared the effects of intravenous ... Cited by 213 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org R Wensel, CF Opitz, R Ewert, L Bruch, FX … - Circulation, 2000 - Am Heart Assoc Methods and Results—In 11 patients with PPH, we performed 2 consecutive
cardiopulmonary exercise tests before and after the inhalation of 17 µg of
iloprost. Patients had marked pulmonary hypertension (mean pulmonary artery ... Cited by 97 - Related articles - BL Direct - All 5 versions
- ►onlinejacc.org N Nagaya, M Uematsu, Y Okano, T Satoh, S … - Journal of the American College of Cardiology, 1999 - Elsevier Twenty-seven patients died of cardiopulmonary causes in the conventional group
during a mean follow-up period of 44 ± 45 months. In contrast, only 4 patients
died of cardiopulmonary causes in the BPS group during a mean follow-up ... Cited by 173 - Related articles - BL Direct - All 11 versions
- ►ersj.org.uk T Gessler, T Schmehl, MM Hoeper, F Rose, … - European Respiratory Journal, 2001 - ersj.org.uk Inhalation of iloprost, a stable prostacyclin analogue, is a promising
perspective in the treatment of pulmonary hypertension. In initial clinical
studies, a conventional jet nebulizer system was successfully used to ... Cited by 89 - Related articles - BL Direct - All 11 versions
- ►annals.org [PDF] DB Badesch, VF Tapson, MD McGoon, BH … - Annals of Internal Medicine, 2000 - Am Coll Physicians David B. Badesch, MD; Victor F. Tapson, MD; Michael D. McGoon, MD; Bruce H.
Brundage, MD; Lewis J. Rubin, MD; Fredrick M. Wigley, MD; Stuart Rich, MD; Robyn
J. Barst, MD; Pamela S. Barrett, PharmD; Kenneth M. Kral, MS; Maria M. ... Cited by 649 - Related articles - BL Direct - All 6 versions
